Phase I clinical study of tumor-specific vaccine using novel tumor antigen SCRN1-derived HLA*0201 restricted epitope peptide against advanced gastric cancer
Phase 1
- Conditions
- Advanced gastric cancer
- Registration Number
- JPRN-UMIN000001013
- Lead Sponsor
- Institute of Medical Science, University of Tokyo
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Inclusion Criteria
Not provided
Exclusion Criteria
pregnancy uncontroled infection uncontroled cerebral metastasis etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of safety and antitumor immune responses
- Secondary Outcome Measures
Name Time Method Clinical efficacy